Section Arrow
MNKD.NASDAQ
- MannKind Corp
Quotes are at least 15-min delayed:2025/04/13 11:47 EDT
Last
 4.66
+0.02 (+0.43%)
Day High 
4.706 
Prev. Close
4.64 
1-M High
5.44 
Volume 
1.94M 
Bid
4.55
Ask
4.68
Day Low
4.54 
Open
4.63 
1-M Low
4.34 
Market Cap 
1.41B 
Currency USD 
P/E 46.4 
%Yield -- 
10-SMA 4.83 
20-SMA 5.02 
50-SMA 5.27 
52-W High 7.63 
52-W Low 3.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.10/0.32
Enterprise Value
1.46B
Balance Sheet
Book Value Per Share
-0.26
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
285.50M
Operating Revenue Per Share
0.58
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed:2025/04/13 11:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.